Halo Labs Closed a $12M Series B1 Financing Round led by Research Corporation Technologies

The Funding Will be Used for Expanding Halo Labs' World-Wide Sales Presence and Continued Development of the Company's Next-Generation Product Portfolio

Wednesday, September 23, 2020

The financing round led by Research Corporation Technologies (RCT). In addition, Halo Labs is actively looking at acquiring complementary technologies and companies to expand into the analytical particle space.

Halo Labs reports the Horizon® instrument performs high throughput subvisible particle (SVP) analysis using volumes as low as 25 µL, ensuring samples can be saved for other analyses or for replicates.  It has a 96-well membrane plate that allows several parameters to be tested in a short amount of time without dilution or sample preparation.

“Horizon is crucial at every stage of biologic drug formulation,” said Chad Souvignier, Vice President of RCT. “In early stages, it can reveal SVP formation missed by other techniques such as light obscuration and flow imaging.  In later stages, it can differentiate proteins from extrinsic particles such as glass and plastic. And given the experience of the Halo Labs management team in product development and Sales, we are eager to find other technologies that we can help bring to market.” Additional backers included BroadOak Capital Partners, BioAdvance, top-level industry executive Paul McEwan, and other current employees.

Halo Labs, Robert Wicke, CEO notes, “The success of Horizon, especially in the Gene Therapy field, provides confirmation that next-generation product development is critical. There is so much more this technology can provide in a variety of markets.” Wicke added, “One of our latest customers, the US FDA, will be using the product to help understand the risks for patients on drug product manufacturing. This is a further indication that Horizon is the product of choice for particle analysis in the subvisible range.

Halo Labs serves customers from the drug discovery phase through formulations and bioprocessing, empowering researchers to learn more about the stability and quality of their biological drugs faster and with more accuracy.  Over the years, Halo Labs has been the recipient of many prestigious awards and has received many research grants from agencies including DARPA, FDA, NSF, NIST, and NIH.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc.

WE WELCOME YOUR VIEWS

Please enter your comment!
Please enter your name here